(Reuters) -The U.S. Food and Drug Administration has approved Otsuka’s injectable drug to treat patients with a potentially life-threatening kidney disease, the health regulator’s website showed on Tuesday.
The drug, branded as Voyxact, was approved to reduce proteinuria in patients with primary immunoglobulin A nephropathy, which causes inflammation in the kidneys and can eventually lead to the organ’s failure.
In a late-stage study, the therapy cut levels of protein in the urine of patients, or proteinuria, by 51.2% in patients after nine months of treatment.
The company did not immediately respond to Reuters’ request for comment on pricing and availability.
(Reporting by Siddhi Mahatole and Sriparna Roy in Bengaluru; Editing by Leroy Leo)
Brought to you by www.srnnews.com
